FDA Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

12.01.2024 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the treatment of ...

Related Keywords

United States ,Canada ,Gursel Aktan ,Foundation Inc ,Statement Of Merck Co Inc ,European Network For Gynaecological Oncological Trial ,Youtube ,Facebook ,Merck Patient Support Program ,Twitter ,Instagram ,Merck Access Program ,Patient Support Program ,Merck Co Inc ,Merck Research Laboratories ,Exchange Commission ,Linkedin ,Important Safety ,Merck Research ,Combined Positive Score ,European Network ,Gynaecological Oncological Trial ,Selected Important Safety ,Important Safety Information ,Fatal Immune Mediated Adverse ,Which Can Present With Diabetic ,Nervous System ,Patients With Multiple ,Neck Squamous Cell ,Bacillus Calmette Guerin ,Mismatch Repair Deficient ,Mismatch Repair Deficient Colorectal ,Support Program ,Looking Statement ,Litigation Reform Act ,Annual Report ,Merck Co Chart ,Erck Co Kurs ,Erck Co Aktie ,